YRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now. YRD just sold off (-5.02% regular session) and is trading below the key pivot (4.051) with weakening upside momentum. With no Intellectia buy signals today and no near-term news catalyst, the risk/reward is not attractive for an impatient entry. A better buy setup would require a decisive reclaim of ~4.05–4.26 or a clean bounce/hold off the 3.84 support area.
Trend/price action: The stock closed at 3.97, below the pivot (4.051), suggesting the near-term trend is tilted bearish/neutral after today’s drop. Momentum: MACD histogram is positive (0.0398) but ‘positively contracting,’ implying bullish momentum is fading rather than accelerating. RSI(6)=43.6 sits in neutral-to-weak territory (no oversold bounce signal). Moving averages: Converging moving averages typically indicate consolidation/indecision—consistent with a choppy range rather than a clean uptrend. Key levels: Support S1=3.841 (nearby), S2=3.711. Resistance R1=4.261 then R2=4.391. With price under pivot, rallies into 4.05–4.26 are likely to face supply. Pattern stats: Based on similar candlestick analogs, the model suggests modest upside odds (next day +0.79% median, next week +3.05%, next month +6.89%), but today’s breakdown below pivot reduces immediate entry quality.
Intellectia Proprietary Trading Signals
Options market positioning is call-heavy (bullish skew) with a volume pickup.
Revenue growth remains positive (2025/Q3 revenue +10.66% YoY).
Upcoming earnings (2026-02-24 pre-market) can act as a tradable catalyst if results/forward commentary improve.
Hedge funds and insiders show neutral activity (no sign of aggressive distribution).
Near-term technical damage: -5.02% session drop and price below the 4.051 pivot.
Momentum is not improving (MACD positive but contracting; RSI below midline).
Profitability trend deteriorated in the latest quarter: net income -10.64% YoY, EPS -10.40% YoY (2025/Q3).
No supportive news flow in the past week to reverse sentiment.
Latest quarter: 2025/Q3. Revenue: 1,408,844,000 (+10.66% YoY) — top-line growth remains healthy. Net income: 317,637,000 (-10.64% YoY) — earnings quality/efficiency weakened. EPS: 1.81 (-10.40% YoY) — confirms profit compression. Overall: Growth is being driven by revenue, but declining net income/EPS signals margin/expense pressure; this mix is not ideal for a momentum-style buy immediately after a selloff.
No analyst rating/price target change data was provided, so there is no confirmed recent trend in upgrades/downgrades or target revisions. Wall Street pro view cannot be validated from the dataset: pros would point to continued revenue growth and potentially cheap small-cap valuation (not provided), while cons would focus on falling net income/EPS and the current weak technical setup.
